Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Core Insights - Structure Therapeutics Inc. announced key leadership appointments to enhance its development and operational success, promoting Blai Coll, M.D., Ph.D. to Chief Medical Officer and appointing Ashley Hall, J.D. as Chief Development Officer [1][2] Leadership Changes - Blai Coll, M.D., Ph.D. has been promoted to Chief Medical Officer, effective September 18, 2024, succeeding Mark Bach, M.D., Ph.D. [1] - Ashley Hall, J.D. has been appointed as Chief Development Officer, a newly created position responsible for clinical development operations, project management, regulatory affairs, and quality assurance [1][2] Clinical Development Focus - The company is advancing its GSBR-1290 program, an oral small molecule GLP-1 agonist, into Phase 2b clinical development for obesity, expected to begin in Q4 2024 [1][2] - Structure Therapeutics aims to expedite the development of its oral amylin compound into clinical trials [2] Leadership Background - Dr. Coll has 15 years of experience in clinical development, previously serving as Vice President of Endocrine and Metabolism Clinical Development at Structure and holding leadership roles at Amgen and AbbVie [3] - Ms. Hall brings 23 years of experience in global clinical development operations and regulatory affairs, having worked on therapies like Repatha® and held leadership positions at Reneo Pharmaceuticals and Esperion Therapeutics [4] Company Overview - Structure Therapeutics is focused on developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions, utilizing a structure-based drug discovery platform [5]